OncoMatch/Clinical Trials/NCT07282912
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
Is NCT07282912 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for foregut adenocarcinoma.
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of the upper gastrointestinal (GI) tract and undetectable ctDNA at the time of randomization after a three-month induction chemotherapy period.
Check if I qualifyExtracted eligibility criteria
Cancer type
Esophageal Carcinoma
Gastric Cancer
Pancreatic Cancer
Cholangiocarcinoma
Disease stage
Required: Stage IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Patients must have at least 4 months of prior effective systemic therapy.
Lab requirements
Blood counts
hemoglobin ≥ 8 g/dL; ANC ≥ 1500/uL; platelet count ≥ 75000/uL; albumin ≥ 3.0 g/dL
Kidney function
creatinine clearance ≥ 50 mL/min
Liver function
total bilirubin ≤ 1.5 times the upper limit of normal (ULN); AST & ALT ≤ 5 times ULN
Cardiac function
No clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from treatment initiation, or New York Heart Association Class III or IV congestive heart failure. Medically controlled arrhythmia stable on medication is permitted.
Has hemoglobin ≥ 8 g/dL. Has ANC ≥ 1500/uL. Has platelet count ≥ 75000/uL. Has total bilirubin ≤ 1.5 times the upper limit of normal (ULN). Has aspartate aminotransferase (AST) & alanine aminotransferase (ALT) ≤ 5 times ULN. Has creatinine clearance ≥ 50 mL/min. Has albumin level less than 3.0 g/dL despite appropriate nutritional support [excluded]. Has clinically significant cardiac disease, including unstable angina, acute myocardial infarction within 6 months from treatment initiation, or New York Heart Association Class III or IV congestive heart failure.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Smilow Cancer Center · New Haven, Connecticut
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify